CSL Behring And SAB Explore Polyclonal Antibodies For COVID-19
Clinical trials Could Start By This Summer
Executive Summary
CSL Behring is backing the US biotech SAB Biotherapeutics in developing polyclonal antibodies in cattle for their efficacy against the pandemic virus, adding a second strand to the research efforts of the blood products specialty company.